Back to homepage

Health Economics & Outcomes Research

Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease

Authors: Christopher M Blanchette, Caihua Liang, Deborah P Lubeck, Britt Newsome, Sandro Rossetti, Xiangmei Gu, Benjamin Gutierrez, Nancy D Lin

Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure. The results of this study suggest that distribution of patients by age at transition to next stage may be useful for identification of ADPKD patients at risk of rapid progression.

More

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Authors: Siddhesh A Kamat, Steve Offord, John Docherty, Jay Lin, Anna Eramo, Ross A Baker, Benjamin Gutierrez, Craig Karson

The results from this large cohort study provided naturalistic real-world evidence of the utility of LAIs in patients with schizophrenia and suggest that these agents may help to reduce the risk of relapse across all age groups, especially among younger patients.

More

Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids’ Inpatient Database

Authors: Bryce A Van Doren, Debosree Roy, Joshua M Noone, Christopher M Blanchette, Susan T Arthur

In this original research article, the authors aimed to characterize the frequency, cost, and hospital reported outcomes of cachexia and debility in children and adolescents with complex chronic conditions (CCCs).

More

Resource use and outcomes associated with initiation of injectable therapies for patients with type 2 diabetes mellitus

Authors: Richard Brice, Sharon Shelley, Pankaj Chaturvedi, Divina Glah, Donna Ashley, Monica Hadi

Management of type 2 diabetes mellitus (T2DM) often requires intervention with oral and injectable therapies. Across National Health Service (NHS) England, injectable therapies may be initiated in secondary, intermediate or primary care. This original research set out to understand resource utilization, the pathways of care, clinical outcomes, and experience of patients with T2DM
initiated on injectable therapies.

More

The cost of biologics for psoriasis is increasing

Authors: Judy Cheng, Steven R Feldman

Biologic agents have revolutionized the management of psoriasis but at a higher cost compared with “traditional” agents. Cost must be considered when evaluating management options for psoriasis. This piece of original research To estimates the annual cost of treatment of psoriasis using biologic agents and assess the trend over the past decade.

More